pioglitazone has been researched along with glutamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alquicer, G; Balcaen, T; Bardova, K; Benova, A; Cajka, T; Dzubanova, M; Ferencakova, M; Funda, J; Horakova, O; Kerckhofs, G; Kopecky, J; Mracek, T; Pecinova, A; Prochazka, J; Rossmeisl, M; Spoutil, F; Tencerova, M; van Lenthe, GH; Willekens, W | 1 |
1 review(s) available for pioglitazone and glutamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for pioglitazone and glutamine
| Article | Year |
|---|---|
Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones.
Topics: Animals; Bone Marrow Stromal Antigen 2; Glucose; Glutamine; Humans; Hypoglycemic Agents; Insulin; Mesenchymal Stem Cells; Mice; Mice, Obese; Obesity; Pioglitazone; PPAR gamma; Spiro Compounds; Thiazolidinediones | 2022 |